5

Introduction
Nitric oxide (NO) is a fundamental regulator of the cardiovascular system. Next to its vasorelaxant and angiogenetic properties, it has also direct cardiac effects (23, 29). Thus, it exerts a negative inotropic effect on contractility, thereby attenuating catecholaminergic effects in myocardium (8, 18, 22) and there is 5 evidence that it influences diastolic relaxation (19) mitochondrial respiration (28) and microcirculation (26, 27) .
In this scheme, the endothelial nitric oxide synthase (eNOS) is regarded to be the predominant generator of nitric oxide (NO) in vascular (23) but also myocardial Less is known about the molecular mechanisms of eNOS activation and their 20 dependence on cytosolic Ca 2+ in cardiac myocytes, where a number of functional and structural differences are known to exist as compared to endothelial cells, among them the drastic beat-to-beat alterations in myocardial cytosolic Ca 2+ 6 concentration. Only recently, have we reported that both eNOS-translocation and ser1177 phosphorylation also occur in human myocardium (10, 34). As cytosolic Ca 2+ concentration is transiently elevated with each heartbeat and is also known to be altered by β-adrenergic stimulation and by several pathologigal states of the heart (4), the degree of Ca 2+ dependence of these mechanisms may have 5 important physiological and pathophysiological implications for the role of NO in the heart.
In this work, we therefore examine eNOS-activation and NO-release in human right atrial myocardium before and after chelating cytosolic Ca 2+ with BAPTA. We therefore use specific antibodies against the translocated form of eNOS, the 10 phosphorylated Akt and the phosphorylated ser1177 eNOS as well as the NO sensitive dye diaminofluorescein (DAF). To elicit agonist induced eNOS activation, we apply the preferential β 3 -adrenoceptor agonist BRL 37344 (1, 18) that we have recently demonstrated to both translocate and ser1177 phosphorylate eNOS (10, 34). Fixation procedures and immunocytochemistry were conducted as described previously (10, 34). To prevent day to day variations in experimental conditions, all immunohistochemical preparates for a specific subset of experiments were 5 done simultaneously in one procedure on the same day under identical conditions. fig. 1 ). Vascular structures of all sizes were frequently found throughout the immunohistochemical preparations and were consistently observed to have higher than average staining for pAkt, pSer1177 eNOS and 10 translocated eNOS ( fig. 1b; arrows) . This is consistent with the relatively higher occurrence of eNOS in endothelial cells (29) . As this study focuses on myocardial tissue only, we have strictly excluded al vascular/endothelial cells from our densitometric quantifications.
Identification of Cell Type (
Negative and Positive Controls for Intensity of Immunostaining (fig. 1). Lowest 15
staining intensity was observed in immunohistochemical controls, i.e. when no specific antibody is used ( fig. 1a) . Maximum staining intensity was observed in endothelial cells of vascular structures, here stained for phosphorylated Ser1177 eNOS ( fig. 1b; arrows) .
TV-densitometry.
For intensity analysis of immunostaining in cardiomyocytes we 20 measured the grey values of 30 cardiomyocytes from three randomly selected areas of each slice. The intensity of immunostaining was reported as the mean of measured cardiomyocyte grey value minus background grey value. The 9 9 background grey value was measured at a cell free area of the slice. For staining intensity detection a Zeiss Axiophot microscope coupled to a 3-chip CCD-camera was used and the analysis was performed using the Optimas 6.01 image analysis program.
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Western Blot Analysis of Ser1177 eNOS Phosphorylation
Tissue pretreatment: For the determination of BRL 37344-induced Ser1177 eNOS phosphorylation, the tissue was pretreated as described above.
In the following, it was shock frozen in liquid nitrogen and then stored at -80° C. 
20
DAF-Fluorometry
Diaminofluorescein (DAF-FM) is converted via an NO-specific mechanism to an intensely fluorescent triazole derivative (24). We used DAF-FM DA to detect changes of the NO level induced by BRL or forskolin. Therefore right atrial myocardial tissue was collected as described above. It was then shock frozen and stored at -80°C. For experiments the tissue was equilibrated at -20°C for at least 1 h and sliced to 25 µM thickness. Slices were fixed to a plastic slide which had been coated with 15% gelatine. Incubation medium was added immediately 5 containing CaCl 2 , MgCl 2 , KCl, NaCl, NaH 2 PO 4 , Glucose, NaHCO 3 and L-arginine negative controls L-NAME (100 µM) was used.
Materials
The preferential β 3 -AR agonist BRL 37344 was obtained by Tocris (Bristol, United Kingdom). The following primary antibodies were used for 20 immunohistochemistry: 1) rabbit anti-eNOS antibody against the bovine eNOS peptide (599-613) plus additional C-terminal Cys conjugated to KLH (PYNSSPREQHKSYKC) (Biomol, Hamburg, Germany); this antibody has been previously shown to be specific in detecting the eNOS-protein after dissociation from caveolin, i.e.after translocation (5, 35). 2) Anti-phospho-Akt/PKB (Upstate, Lake Placid, USA), corresponding to aminoacids 301-312 of mouse pAkt/PKB and 3) anti-phospho-eNOS Ser1177 (Upstate, Lake Placid, USA), corresponding to aminoacids 1172-1183 of human eNOS. As secondary antibodies a biotinylated 5 goat anti-rabbit, or biotinylated goat anti-mouse antibody (Dako, Hamburg, Germany) was used for accentuation.
Further substances used were the cell permeant Ca
(Calbiochem, Germany), the NO-sensitive dye diaminofluorescein (DAF-FM), 10 (Molecular Probes, Eugene, Oregon, USA), the NO-inhibitor N-nitro-L-arginine (L-NAME), (Buchs, Switzerland) and the NO-donor spermine-NONOate (Alexis, Grünberg, Germany).
All other chemicals were of analytical grade or the best grade, commercially available. For studies with isolated myocardium and trabeculae, stock solutions 15 were prepared and added to the organ bath. All compounds were dissolved in twice distilled water and did not change the pH of the medium.
Statistical Analysis
Means were compared between groups and across time using repeated measure 20 analysis of variance (ANOVA) methods. Pair wise mean comparisons were made using the Tukey-Fisher criterion under repeated measure ANOVA model (JMP 5.01a, SAS Institute, Cary, NC).
Results
eNOS-Translocation
To assess eNOS-activation by translocation of the enzyme in the absence and presence of BAPTA, we performed immunohistochemical eNOS stainings in 5 isolated, right atrial non-failing trabeculae under control conditions (t=0 min) and after application of the preferential β 3 -adrenoceptor agonist and eNOS-activator BRL 37344 (BRL; 10 µM, t=5 min). We therefore used an eNOS-antibody which has been shown to specifically detect the activated, translocated eNOS protein 
ser1177 eNOS-Phosphorylation
We have recently shown that BRL induces an Akt dependent phosphorylation of ser1177 eNOS in human myocardium (10). To test whether this effect is also influenced by Ca 2+ chelation, the effects of BRL on ser1177 eNOS-and Aktphosphorylation were assessed in the presence of BAPTA. We therefore again conducted immunohistochemical experiments, this time using specific antibodies against phosphorylated Akt and phosphorylated ser1177 eNOS (10, 12). Although BAPTA (20 µM; 20 min) was present, BRL led to a strong increase of both 5 phosphorylated ser1177 eNOS ( fig. 3 a, b ) and phosphorylated Akt ( fig. 3 c, d ) as compared to basal conditions (fig 3 a, c) . The densitometric quantification ( fig. 4) shows an increase in staining intensity of +148.1±39.2% (p<0.05) for To confirm these results, we additionally conducted Western blots using the specific antibody against ser1177 eNOS in homogenates from right atrial myocardium ( fig. 5 ). BRL increased ser1177 eNOS phosphorylation in the absence 15 of BAPTA (+BRL: +73±21%; n=3 patients; p<0.05). Consistent with our immunohistochemical experiments, this process was undisturbed when repeated in the presence of BAPTA (+BRL: +76±16%; n=4 patients; p<0.05).
NO-Release 20
The fluorescent NO-sensitive dye DAF (24) was used to measure agonist induced NO-release in the presence and absence of BAPTA. To demonstrate the reliability of these findings, the effect of BRL on NO-release 15 was also tested in the presence of the NO-inhibitor L-NAME (100 µM). As expected, BRL did not increase fluorescence in this situation (n=4; +BRL+L-NAME: -11±3%). For positive method control, the NO-donor NONOate (10 µM) was applied which significantly raised fluorescence (n=3; +118±7%; p<0.05 versus control by 2-way ANOVA). A further positive control was conducted using 20 the NO-substrate L-arginine (10 mM)(n=3; +137±35%; p<0.05 versus control by 2-way ANOVA).
Effects of Forskolin on eNOS-Translocation and NO-Release
As β-adrenergic stimulation is mediated via an adenylate cyclase activated increase in cytosolic Ca 2+ , we asked the question whether this may directly influence myocardial eNOS-activation. We therefore tested the effects of the adenylate cyclase activator forskolin (0.3 µM) on eNOS-translocation and NO 5 release in immunohistochemical and DAF experiments (Fig. 7) . Forskolin neither affected eNOS-translocation ( fig. 7a,b) nor did it change NO-level ( fig. 7c,d ).
Discussion
The present study investigated the effects of cytosolic Ca 2+ depletion on eNOSactivation in human right atrial myocardium. It was shown that agonist induced translocation of eNOS is abolished after depletion of cytosolic Ca 2+ , whereas in this situation Akt dependent ser1177 eNOS phosphorylation persists. We could 5 furthermore demonstrate that despite persistent ser1177 eNOS phosphorylation, no agonist induced NO-release was detected in the presence of 20 µM of the Ca 2+ chelator BAPTA. Accordingly, when Akt-induced ser1177eNOS phosphorylation was blocked, BRL induced NO release remained undisturbed.
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Translocation and Phosphorylation of eNOS
The molecular mechanisms of eNOS-activation have well been defined in vascular tissue. Thus, it is known that eNOS-activation occurs via dissociation from caveolin and subsequent translocation into the cytosol, a process which requires binding of calmodulin and thus a raise in cytosolic Ca 2+ (5, 29, 30) . 15
Dimmeler and Fulton (12, 16) were the first to recognize that the phosphorylation of eNOS poses an alternative mechanism of eNOS-activation in endothelial cells that occurs independently from eNOS-translocation and calmodulin-binding and thus would not require cytosolic Ca 2+ . Only recently, we were able to evidence that agonist induced ser1177 phosphorylation of eNOS not only occurs in 20 endothelium but also in human myocardium (10).
In the present study, myocardial eNOS-translocation was abolished after depletion of cytosolic Ca 2+ , a finding which is consistent with the theory of show that Ca 2+ dependent and Ca 2+ independent molecular mechanisms of 10 eNOS activation not only occur in endothelium but also in atrial cardiomyocytes.
As to the present, Ca 2+ independent eNOS-phosphorylation has not been observed to occur as a consequence of agonist stimulation, it is furthermore most notable that in this study we were able to elicit it by stimulation with the β 3 -adrenoceptor agonist BRL 37344. 15
NO-Release
In endothelial cells, a release of NO subsequent to phosphorylation of eNOS, has been reported to occur even in the absence of Ca 2+ though usually with delayed kinetics, i.e. with a maximum between 5-10 minutes (7, 14, 20, 32, 40 10 independent regulation of eNOS in endothelial cells (3, 6, 13, 31). We cannot exclude that BRL may fail to act via this phosphorylation site and that only the convergence of phosphorylation at Ser635 and Ser1177 may in the end be decisive for Ca 2+ independent eNOS activity in atrial cardiomyocytes.
Also, β-adrenoceptor distribution and coupling have been reported to differ 15 between atrium and ventricle (36-38). As we have evidenced that eNOSactivation in ventricular myocytes occurs without eNOS-translocation (10), ser1177 eNOS-phosphorylation may be of much greater significance for NOproduction in ventricular myocytes as compared to atrial myocardium. 
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Lack of Effects of Forskolin
β 1 -
Functional Implications
Our study shows that NO release in human atrium is Ca 2+ dependent and that Ca 2+ independent phosphorylation, although existent in human atrium, does not substantially contribute to NO production. This may be different in human ventricle, were NO production seems to depend on eNOS phosphorylation and 15 would therefore be independent of cytosolic Ca 2+ (10). Thus, eNOS turnout in human atrium could be much more dependent on beat-to-beat changes in cytosolic Ca 2+ as compared to ventricular myocardium which may result in differences in contractile regulation between atrium and ventricle. Also, longer term changes in diastolic and systolic Ca 2+ concentration as they occur during 20 hypertrophy and heart failure (4) could potentially have greater effects on atrial than on ventricular NO metabolism. Stretch activated cardiac NO release on the other hand, which is known to be mediated via Ca 2+ independent eNOS 21 21 phosphorylation (33) would thus have more pronounced effects in ventricle than atrium. Finally, the fact that NO release in atrium is Ca 2+ dependent could play an important role during ischemia reperfusion injury, where an increase in cytosolic Ca 2+ mediates myocardial damage (21).
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Summary
In conclusion, this work shows, that in human atrial myocardium, receptor mediated eNOS-translocation is dependent on intracellular Ca 2+ whereas receptor mediated ser1177 eNOS-phosphorylation is not. In this, it is consistent with the current picture of eNOS-activation in the endothelium and extends this 10 knowledge to the atrial myocardium. Furthermore we demonstrate that in atrial myocardium, eNOS-translocation and not 1177 eNOS-phosphorylation generates bulk NO upon agonist stimulation. It was also evidenced that though Ca 
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